8-K: Cardinal Health Q3 FY26: Revenue Up 11%, Non-GAAP EPS Soars 35%

Cardinal Health reported strong third quarter fiscal year 2026 results, with revenue increasing 11% to $60.9 billion and non-GAAP diluted EPS rising 35% to $3.17, leading the company to raise its full-year outlook.

Summary

• Cardinal Health announced its third quarter fiscal year 2026 results, with revenue reaching $60.9 billion, an 11% increase year-over-year.
• GAAP operating earnings decreased by 30% to $509 million, impacted by a $184 million goodwill impairment in the Navista & ION reporting unit.
• Non-GAAP operating earnings saw a significant increase of 18% to $956 million.
• Non-GAAP diluted earnings per share (EPS) surged by 35% to $3.17.
• The company has raised and narrowed its fiscal year 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80.
• Debt was reduced, and an additional $250 million in share repurchases were completed, bringing the total FY26 repurchase to $1.0 billion.
• The Pharmaceutical and Specialty Solutions segment revenue grew 11% to $56.1 billion, with segment profit up 18% to $784 million.
• The 'Other' segment, including at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics, saw revenue increase by 31% to $1.7 billion and profit rise by 34% to $179 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, substantial increases in non-GAAP earnings and EPS, and a raised full-year outlook, despite some GAAP-specific impairments.

Positives

• Revenue increased by 11% to $60.9 billion in the third quarter of fiscal year 2026.
• Non-GAAP operating earnings increased by 18% to $956 million.
• Non-GAAP diluted EPS increased by 35% to $3.17.
• The company raised its fiscal year 2026 non-GAAP EPS guidance to $10.70 - $10.80.
• Pharmaceutical and Specialty Solutions segment profit increased by 18% to $784 million.
• The 'Other' segment profit increased by 34% to $179 million, driven by growth in at-Home Solutions, OptiFreight Logistics, and Nuclear and Precision Health Solutions.
• Debt was reduced, and the leverage ratio was lowered to 3.0X, maintaining the targeted range.
• An additional $250 million share repurchase was completed, totaling $1.0 billion for FY26.

Negatives

• GAAP operating earnings decreased by 30% to $509 million.
• GAAP diluted EPS decreased by 20% to $1.69.
• A $184 million pre-tax goodwill impairment was recorded in the Navista & ION reporting unit.
• Global Medical Products and Distribution segment profit decreased by 36% to $25 million, primarily due to the adverse net impact of tariffs.
• Interest and other expense increased by 36% to $101 million for the quarter.

Risks

• Uncertainties associated with the pricing of branded pharmaceuticals, including proposed or final regulatory changes.
• The risk of failing to achieve strategic objectives, including the operation of recently acquired entities and execution of the GMPD Improvement Plan.
• Risks and uncertainties related to tariffs, including the inability to offset increased costs or potential loss of customers if competitors do not increase prices similarly.
• Competitive pressures in various lines of business, including the risk of customers reducing purchases or terminating contracts.
• Risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Events outside of Cardinal Health's control, such as weather or geopolitical events (including the recent conflict with Iran), may impact product costs, cause supply delays or shortages, or manufacturing delays.
• The performance of the generics program, including the amount or rate of generic deflation and the ability to offset it.
• Potential for supply delays or shortages due to geopolitical events.

Future Outlook

Cardinal Health has raised and narrowed its fiscal year 2026 non-GAAP diluted EPS guidance to a range of $10.70 to $10.80, representing 30% to 31% growth. This updated guidance reflects improved operating segment performance, particularly in Pharmaceutical and Specialty Solutions and the 'Other' segment, a lower non-GAAP effective tax rate, and a decrease in diluted weighted average shares outstanding. Adjusted free cash flow guidance has also been raised and narrowed to $3.3 billion to $3.7 billion.

Management Comments

• "An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business," said Jason Hollar, CEO of Cardinal Health.
• "We were pleased to see strong operating performance led by Pharmaceutical and Specialty Solutions and our three growth businesses, positioning us for long-term value creation and giving us the confidence to again raise our fiscal 2026 outlook."

Industry Context

StockSavvy.ai notes that Cardinal Health's performance in Q3 FY26, particularly the strong revenue growth and increased non-GAAP EPS, aligns with a trend of resilience in the healthcare distribution sector. The company's ability to raise its full-year outlook despite GAAP headwinds suggests robust underlying operational execution and strategic positioning within key growth areas like specialty pharmaceuticals and at-home solutions.

Comparison to Industry Standards

• Cardinal Health's 11% revenue growth in Q3 FY26 outpaces the typical growth rates seen in the broader healthcare distribution sector, which often experiences single-digit growth.
• The 35% increase in non-GAAP diluted EPS is a significant outperformance compared to many peers, indicating strong operational leverage and effective cost management.
• The company's focus on specialty solutions and at-home care aligns with industry trends towards personalized medicine and decentralized healthcare delivery, areas where competitors like McKesson and AmerisourceBergen are also investing.

Legal Proceedings

• Potential violations of the Anti-Kickback Statute and False Claims Act are under investigation by the Department of Justice.

Stakeholder Impact

• Shareholders: Benefit from increased non-GAAP EPS, raised guidance, and ongoing share repurchases.
• Employees: May see continued focus on operational performance and strategic growth initiatives.
• Customers: Benefit from continued strong performance in pharmaceutical and specialty solutions distribution, though potential tariff impacts on medical products could be a concern.
• Creditors: Benefit from debt reduction and maintained investment-grade rating.

Next Steps

• Continue to monitor performance against the raised fiscal year 2026 outlook.
• Evaluate the impact of the goodwill impairment on future financial reporting.
• Observe the ongoing execution of growth strategies in Pharmaceutical and Specialty Solutions and the 'Other' segment.
• Monitor the company's debt reduction and share repurchase activities.

Key Dates

Recommendation

The company demonstrated robust top-line growth, significant improvement in non-GAAP profitability and EPS, and a raised full-year outlook. The strategic focus on growth areas and effective capital allocation (debt reduction, share repurchases) present a compelling investment case, outweighing the GAAP-specific goodwill impairment.

Keywords

Cardinal Health, SEC Filing, 8-K, Quarterly Results, Financial Performance, Revenue Growth, EPS Guidance, Pharmaceutical Distribution